14925-39-4

Basic information

• Product Name: 2-BROMO-PROPENAL
• Synonyms: 2-BROMO-PROPENAL;2-bromoacrolein;ALPHA-BROMOACROLEIN;2-Bromo-acrylaldehyde, 2-Bromopropenal;2-Bromo-2-propenal;2-Bromoacrylaldehyde;α-Bromoacrolein;2-bromoprop-2-enal
• CAS NO: 14925-39-4
• Molecular Formula: C₃H₃BrO
• Molecular Weight: 134.95932
• Product Categories: Acyclic;Aldehydes;Alkenes;Building Blocks;C1 to C6;Carbonyl Compounds;Chemical Synthesis;Organic Building Blocks
• Mol File: 14925-39-4.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 149.1°Cat760mmHg
• Flash Point: 97°C
• Appearance: /
• Density: 1.3014 (rough estimate)
• Vapor Pressure: 4.08mmHg at 25°C
• Refractive Index: 1.4562 (estimate)
• Storage Temp.: ?20°C
• BRN: 1698247
• CAS DataBase Reference: 2-BROMO-PROPENAL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-PROPENAL(14925-39-4)
• EPA Substance Registry System: 2-BROMO-PROPENAL(14925-39-4)

Safety Data

• Hazard Codes: T,N
• Statements: 23/24/25-34-50
• Safety Statements: 26-36/37/39-45-61
• RIDADR: UN3286 3/PG 2
• WGK Germany: 3
• RTECS: AS1110000
• Hazardous Substances Data: 14925-39-4(Hazardous Substances Data)

Usage

General Description

2-Bromo-propenal is a chemical compound with the formula C3H3BrO. It is a highly reactive and potentially toxic compound used in organic synthesis. 2-Bromo-propenal is commonly used as a reagent in chemical reactions, particularly in the production of fine chemicals and pharmaceuticals. It is also used in the synthesis of other compounds such as pharmaceutical intermediates, agrochemical intermediates, and organic intermediates. The compound is considered hazardous and should be handled with caution, as it has the potential to cause irritation to the skin, eyes, and respiratory system if not used properly. Additionally, it may have adverse environmental impacts and should be properly disposed of to prevent harm to the ecosystem.

InChI:InChI=1/C3H3BrO/c1-3(4)2-5/h2H,1H2

Upstream product

• 5221-17-0 2,3-dibromopropanal 
• 7732-18-5 water 
• 127-09-3 sodium acetate 
• 7726-95-6 bromine 
• 107-02-8 acrolein 
• 83769-10-2 (2-Bromo-3-oxo-propyl)-dimethyl-sulfonium; bromide 

Downstream Products

• 675129-83-6 4-bromo-3-(4-bromophenyl)-2-phenylisoxazolidine-4-carbaldehyde 
• 675129-86-9 4-bromo-3-(1-naphthyl)-2-phenylisoxazolidine-4-carbaldehyde 
• 41894-54-6 1-bromo-3,4-dimethylcyclohex-3-enecarbaldehyde 
• 41894-55-7 1-Bromo-2,5-diphenyl-cyclohex-3-enecarbaldehyde 
• 6630-39-3 2-bromo-1,1,3-triethoxy-propane 
• 288-13-1 NH-pyrazole 
• 1350707-57-1 tert-butyl (1S,2R)-2-bromo-2-formyl-1-o-tolylcyclopropanecarboxylate 
• 1350707-14-0 tert-butyl (1S,2R)-2-bromo-2-formyl-1-phenylcyclopropanecarboxylate 

Relevant articles and documents

Halogen-Bonding-Induced Conjugate Addition of Thiophenes to Enones and Enals

Herein, we report the conjugate addition of α,β-unsaturated carbonyl compounds to thiophene derivatives. We used a 2-iodoimidazolinium triflate salt as a halogen-bonding donor, which afforded moderate-to-excellent yields of the corresponding alkylated thi

A 5 - bromo -2 - methyl nicotinic acid ethyl ester

The invention discloses a 5 - bromo - 2 - methyl nicotinic acid ethyl ester synthetic method, comprises the following steps: the acetyl ethyl acetate and alkali A adding solvent in the B enolizable; adding intermediate III and DABCO reaction; adding ammonium to cyclization; adding water quenching, organic solvent extraction C; removing the organic solvent to be crystalline crude product shall C; to be crystalline crude product recrystallized from 5 - bromo - 2 - methyl nicotinic acid ethyl ester; the invention to Meck development of 5 - chloro - 2 - methyl nicotinic acid ethyl ester is based on, through changing the reaction solvent and reduce the reaction temperature, significantly improves the stability of the intermediate III, so that the reaction can be smoothly to obtain the product, after treatment through recrystallization purification, thus avoiding the time-consuming column chromatography process, the average yield of 70%, the purity of 99.0% or more, is suitable for the large-scale industrial production.

HETEROCYCLIC COMPOUND

The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.